Silke Paust

Scripps Research Institute — United States

Immunology and Microbiology · Life Sciences

28h-index4.2kcitations88works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(34), Neuroblastoma Research and Treatments(21), T-cell and B-cell Immunology(19), Immunotherapy and Immune Responses(12), Cancer, Hypoxia, and Metabolism(11)

Publications88 total

Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations
Science Advances·2025· 2 citedOpen Access
CMV-specific clonal expansion of Th1, GZMK⁺ CD8⁺, and TEMRA T cells revealed by human PBMC single cell profiling
2025· 1 citedOpen Access
TRAIL-mediated PMN-MDSC depletion prevents CD4 <sup>+</sup> T cell loss in HIV-infected humanized mice
2025
Infants display reduced NK cell responses in RSV and increased inflammatory responses in SARS-CoV-2 infections
2025· 1 citedOpen Access
Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy
Frontiers in Immunology·2024· 15 citedOpen Access
Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults
Nature Immunology·2024· 29 citedOpen Access
Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults
2023· 4 citedOpen Access
Supplementary Figure 3 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Data from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Data from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Information from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 1 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Shawn Abeynaike(8), Rana Nikzad(7), Duy T. Le(7), Lynn Bimler(6), Ulrich H. von Andrian(5), Laura S. Angelo(5), Farrah Kheradmand(5), William K. Decker(4), Bryan M. Burt(4), Cristina Zalfa(4), Harvey Cantor(3), Kevin Aviles-Padilla(3), Emily M. Mace(3), Iván K. Chinn(3), Shalini N. Jhangiani(3), Donna M. Muzny(3), Asbjørg Stray‐Pedersen(3), Zeynep Coban‐Akdemir(3), Richard A. Gibbs(3), James R. Lupski(3)